stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Treatment and conditionWhere it standsTrials
stereotactic ablative radiotherapy + TESTOSTERONE + LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for prostatic neoplasmsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1